Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 28, 2026
TickeronGET DAILY SIGNALS
Why Is CalciMedica (CALC) Stock Down 1.71% Today?

Why Is CalciMedica (CALC) Stock Down 1.71% Today?

Key Takeaways

  • CALC shares declined roughly 1.71% to $1.72, down from the prior session's close of $1.75.
  • The pullback lacked a single company-specific catalyst, reflecting a broader cautious tone across micro-cap biotechnology.
  • Elevated volatility is characteristic of this low-float, clinical-stage developer following its recent 1-for-5 reverse stock split and Nasdaq compliance restoration.
  • The move comes amid profit-taking after a sharp, analyst-driven rebound in the stock during August and September.
  • Traders are watching the company's pulmonary hypertension pipeline and its next earnings report, expected around November 11, 2026.

Opening Summary

CALC, the common stock of CalciMedica, Inc., a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory, immunologic, and cardiopulmonary diseases, traded lower in Monday's session. The stock slipped about 1.71% to $1.72, compared with a prior closing price of $1.75, confirming a modestly negative session for the small-cap name. Markets attributed the decline less to any single headline and more to a combination of profit-taking, thin trading liquidity, and cautious sentiment toward speculative biotech equities.

No Single Catalyst: A Liquidity-Driven Pullback

Unlike a move driven by an earnings beat, a regulatory decision, or an analyst action, Monday's decline in CALC did not coincide with a major corporate announcement. CalciMedica is a low-float, early-stage developer with a market capitalization in the low tens of millions of dollars, a profile that makes its shares unusually sensitive to modest shifts in buying and selling pressure. With relatively thin trading volume, even routine profit-taking can translate into a visible percentage move, and that dynamic was on display as the stock drifted from its prior close toward the $1.72 level.

Post-Reverse-Split Volatility and Recent Rally Context

The stock's recent trajectory provides important context for today's action. CalciMedica completed a 1-for-5 reverse stock split effective August 31, 2026, a move intended to restore compliance with Nasdaq's minimum bid price requirement. The company subsequently confirmed on September 15, 2026, that it had regained compliance after its shares closed at or above $1.00 for ten consecutive business days. That resolution removed an immediate delisting overhang and helped fuel a sharp rally earlier in the month, supported by an upbeat analyst environment that included a Guggenheim initiation with a Buy rating and a materially higher consensus price target.

Following such a rapid advance, some degree of consolidation is normal, and Monday's modest decline can be read as a continuation of that digestion process rather than a fundamental shift in the company's outlook. The stock has also pulled back from its early-September highs, reflecting the inherent back-and-forth of a micro-cap that remains heavily influenced by technical and sentiment factors.

Broader Market and Sector Sentiment

The decline in CALC also unfolded against a backdrop of cautious risk appetite across speculative, pre-revenue biotechnology names. Clinical-stage biotechs with no approved products tend to trade in sympathy with investor willingness to hold higher-risk, longer-duration assets. When broader risk sentiment cools or when investors rotate toward more defensive positioning, thinly traded development-stage companies are often among the first to see incremental selling, even in the absence of company-specific news.

Market Context and Trading Activity

Trading in CALC remained relatively light relative to the elevated volumes seen during its August–September rally, which is typical of a consolidating micro-cap. The stock continues to trade well below its 50-day and 200-day moving averages, underscoring the extended nature of its prior multi-month decline and the technical work still required for a sustained recovery. While the company regained Nasdaq listing compliance, it remains a high-beta, low-float name whose day-to-day price action can diverge meaningfully from broader indices and larger biotech peers.

What Comes Next for CALC

Looking ahead, investors will focus on execution across CalciMedica's pulmonary hypertension program, which features its intravenous candidate Auxora and the oral CRAC channel inhibitor CM5480. The company has signaled plans to advance a Phase 1b proof-of-concept study in pulmonary arterial hypertension and expects an IND submission for CM5480 in mid-2027. Its next quarterly earnings report is anticipated around November 11, 2026, and will be closely watched for updates on cash runway, clinical timelines, and pipeline progress. Key risks include the inherent uncertainty of clinical development, the need for additional capital to fund operations, and continued volatility associated with a small float and heavy reliance on sentiment. These factors, rather than any single headline, are likely to shape the stock's near-term path.

Trending AI Robots

For traders seeking a more systematic approach to names like CALC, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore data-driven approaches across different market environments. Visit the page to see which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CALC

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


CALC's RSI Oscillator ascending out of oversold territory

The RSI Indicator for CALC moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 26 of the 31 cases the stock moved higher. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CALC advanced for three days, in 185 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CALC as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

CALC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CALC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.684) is normal, around the industry mean (3.596). P/E Ratio (-0.199) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CALC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
505 Coast Boulevard South
Phone
+1 858 952-5500
Employees
16
Web
https://www.calcimedica.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.